RERF-LC-MSHomo sapiens (Human)Cancer cell line

Also known as: Radiation Effects Research Foundation-Lung Cancer-MS, LCMS, LC-MS, RERFLCMS, RERF-LCMS, REAF-LC-MS

🤖 AI SummaryBased on 13 publications

Quick Overview

Human lung cancer cell line with EGFR mutations and genetic heterogeneity.

Detailed Summary

RERF-LC-MS is a human lung cancer cell line derived from Japanese patients, characterized by the presence of EGFR mutations and genetic heterogeneity. This cell line has been extensively studied for its role in understanding the molecular mechanisms of lung cancer, particularly in relation to tyrosine kinase inhibitor sensitivity. Research has shown that RERF-LC-MS exhibits subpopulations with distinct EGFR mutations, highlighting the complexity of tumor genetics. The cell line is also used to investigate the impact of genetic alterations on drug response and cancer progression.

Research Applications

EGFR mutation analysisGenetic heterogeneity studiesDrug response profilingCancer progression research

Key Characteristics

Presence of EGFR mutationsGenetic heterogeneitySubpopulation variabilityRelevance to lung cancer research
Generated on 6/17/2025

Basic Information

Database IDCVCL_1655
SpeciesHomo sapiens (Human)
Tissue SourceLung[UBERON:UBERON_0002048]

Donor Information

Age CategoryUnknown
SexMale
Raceasian

Disease Information

DiseaseLung adenocarcinoma
LineageLung
SubtypeLung Adenocarcinoma
OncoTree CodeLUAD

DepMap Information

Source TypeJCRB
Source IDACH-000062_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Arg248Leu (c.743G>T)Unspecified-PubMed=18487078

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X,Y
CSF1PO
12,13
D13S317
10
D16S539
12
D18S51
16
D21S11
30
D3S1358
16
D5S818
10,13
D7S820
11,12
D8S1179
11,14
FGA
24
Penta D
10
Penta E
14,15
TH01
7
TPOX
8,11
vWA
16
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.

Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.

Cancer Sci. 101:1891-1896(2010).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

A gene-alteration profile of human lung cancer cell lines.";

Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.

Hum. Mutat. 30:1199-1206(2009).

Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp.

Fukuyama S., Yokote A., Kobayashi K., Kanazawa M., Hagiwara K.

Cancer Res. 65:7276-7282(2005).

Determinants of cisplatin and irinotecan activities in human lung adenocarcinoma cells: evidence of cisplatin accumulation and topoisomerase I activity.

Tabata M., Ueoka H., Tanimoto M.

In Vivo 19:717-721(2005).

Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers.

Hirohashi S., Inazawa J., Imoto I.

Hum. Mol. Genet. 14:997-1007(2005).

TERC identified as a probable target within the 3q26 amplicon that is detected frequently in non-small cell lung cancers.

Yokoi S., Yasui K., Iizasa T., Imoto I., Fujisawa T., Inazawa J.

Clin. Cancer Res. 9:4705-4713(2003).

Expression of tetraspanins in human lung cancer cells: frequent downregulation of CD9 and its contribution to cell motility in small cell lung cancer.

Hayashi S., Aozasa K., Kawase I.

Oncogene 22:674-687(2003).

Mutation and expression of the DCC gene in human lung cancer.";

Yokota J.

Neoplasia 2:300-305(2000).

Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes.

Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J.

Int. J. Oncol. 15:927-934(1999).

Establishment of a drug sensitivity panel using human lung cancer cell lines.

Kohara H., Harada M.

Acta Med. Okayama 53:67-75(1999).

Screening the p53 status of human cell lines using a yeast functional assay.

Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.

Mol. Carcinog. 19:243-253(1997).

HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.

Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.

Cell. Immunol. 175:101-110(1997).

Inhibitory effects of cholera toxin on in vitro growth of human lung cancer cell lines.

Kiura K., Watarai S., Shibayama T., Ohnoshi T., Kimura I., Yasuda T.

Anticancer Drug Des. 8:417-428(1993).

Gene analysis of K-, H-ras, p53, and retinoblastoma susceptibility genes in human lung cancer cell lines by the polymerase chain reaction/single-strand conformation polymorphism method.

Kashii T., Mizushima Y., Monno S., Nakagawa K., Kobayashi M.

J. Cancer Res. Clin. Oncol. 120:143-148(1994).

In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers.

Takahashi T., Takahashi T.

Cancer Res. 55:514-517(1995).